Trial · NCT04338321
Results by group882
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 882
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With Remission as Assessed by the Montgomery-Asberg Depression Rating Scale (MADRS) Score at Week 8 | Esketamine Nasal Spray + Oral Antidepressant (AD) | 27.1 | Percentage of participants | ||
| Percentage of Participants With Remission as Assessed by the Montgomery-Asberg Depression Rating Scale (MADRS) Score at Week 8 | Quetiapine Extended Release (XR) + Oral AD | 17.6 | Percentage of participants | ||
| Percentage of Participants With Both Remission at Week 8 and Relapse-free Until Week 32 | Esketamine Nasal Spray + Oral Antidepressant (AD) | 21.7 | Percentage of Participants | ||
| Percentage of Participants With Both Remission at Week 8 and Relapse-free Until Week 32 | Quetiapine Extended Release (XR) + Oral AD | 14.1 | Percentage of Participants | ||
| Change From Baseline in Clinician-rated Overall MADRS Score | Esketamine Nasal Spray + Oral Antidepressant (AD) | Week 1 | -5.3 | Standard Deviation 5.71 | Unit on scale |
| Change From Baseline in Clinician-rated Overall MADRS Score | Quetiapine Extended Release (XR) + Oral AD | Week 1 | -3.7 | Standard Deviation 4.65 | Unit on scale |
| Change From Baseline in Clinician-rated Overall MADRS Score | Esketamine Nasal Spray + Oral Antidepressant (AD) | Week 2 | -9.0 | Standard Deviation 6.87 | Unit on scale |
| Change From Baseline in Clinician-rated Overall MADRS Score | Quetiapine Extended Release (XR) + Oral AD | Week 2 | -6.1 | Standard Deviation 6.52 | Unit on scale |
| Change From Baseline in Clinician-rated Overall MADRS Score | Esketamine Nasal Spray + Oral Antidepressant (AD) | Week 4 | -12.8 | Standard Deviation 7.50 | Unit on scale |
| Change From Baseline in Clinician-rated Overall MADRS Score | Quetiapine Extended Release (XR) + Oral AD | Week 4 | -9.8 | Standard Deviation 7.32 | Unit on scale |
| Change From Baseline in Clinician-rated Overall MADRS Score | Esketamine Nasal Spray + Oral Antidepressant (AD) | Week 6 | -14.9 | Standard Deviation 8.27 | Unit on scale |
| Change From Baseline in Clinician-rated Overall MADRS Score | Quetiapine Extended Release (XR) + Oral AD | Week 6 | -12.2 | Standard Deviation 8.11 | Unit on scale |
| Change From Baseline in Clinician-rated Overall MADRS Score | Esketamine Nasal Spray + Oral Antidepressant (AD) | Week 8 | -16.4 | Standard Deviation 8.67 | Unit on scale |
| Change From Baseline in Clinician-rated Overall MADRS Score | Quetiapine Extended Release (XR) + Oral AD | Week 8 | -14.3 | Standard Deviation 8.26 | Unit on scale |
| Change From Baseline in Clinician-rated Overall MADRS Score | Esketamine Nasal Spray + Oral Antidepressant (AD) | Week 10 | -18.2 | Standard Deviation 8.32 | Unit on scale |
| Change From Baseline in Clinician-rated Overall MADRS Score | Quetiapine Extended Release (XR) + Oral AD | Week 10 | -16.2 | Standard Deviation 7.38 | Unit on scale |
| Change From Baseline in Clinician-rated Overall MADRS Score | Esketamine Nasal Spray + Oral Antidepressant (AD) | Week 12 | -18.4 | Standard Deviation 8.26 | Unit on scale |
| Change From Baseline in Clinician-rated Overall MADRS Score | Quetiapine Extended Release (XR) + Oral AD | Week 12 | -16.7 | Standard Deviation 8.16 | Unit on scale |
| Change From Baseline in Clinician-rated Overall MADRS Score | Esketamine Nasal Spray + Oral Antidepressant (AD) | Week 14 | -19.0 | Standard Deviation 8.06 | Unit on scale |
| Change From Baseline in Clinician-rated Overall MADRS Score | Quetiapine Extended Release (XR) + Oral AD | Week 14 | -17.1 | Standard Deviation 8.06 | Unit on scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04338321/results